William Farnaby is a Principal Investigator within the Centre for Targeted Protein at the University of Dundee. Previously, whilst in the group of Alessio Ciulli, Will led a targeted protein degradation drug discovery team engaged in a collaboration between the University of Dundee and Boehringer Ingelheim. During this time Will progressed a number of protein degradation projects through key drug discovery milestones and authored highly cited studies detailing novel approaches for the design and characterisation of degrader molecules. Prior to this Will worked at Takeda as a senior medicinal chemist, co-inventing Soticlestat and Luvadaxistat, inhibitors currently under late-stage clinical evaluation in the Central Nervous System therapeutic area. He is now initiating his own academic program focussed on using induced proximity chemistry to provide breakthroughs in understanding and treating neurodegenerative diseases.